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Abstract: Elevated lipoprotein(a) [Lp(a)]
concentrations are associated with premature
coronary heart disease and early myocardial
infarction. In the general human population
the sizes of apolipoprotein [apo(a)] isoforms
are inversely associated with lipoprotein(a)
levels. Large isoforms are associated with low
Lp (a) and small isoforms with high Lp(a) in
the plasma. The size of the polymophism is
directly correlated with the number of
kringle-4 domains in apo(a). It has been
shown by quantitative Southern blotting, and
more recently by pulsed-field gel
electrophoresis, that polymophism is the
result of differences in the number of tandem
kringle-4 repeats in the apo(a) gene.

apo(a) gene and does not detect other

In our current study, we used a digoxigenin
labeled MP-1 probe which is specific for the
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Introduction
Lp(a) represents a class of lipoprotein particles
defined by the presence of apo(a), a unique glycoprotein
linked by a disulfide bond to apolipoprotein B-100 to
form a single macromolecule (1). Apo(a) contains three
different structural domains each having high amino acid
sequence homology with plasminogen. One of the
domains, called kringle-4, is present in multiple copies,
the number of which varies and is genetically determined.
This accounts for the size heterogeneity of apo(a) and
thus of Lp(a) (2-5). The size variation is inversely related
to the plasma concentration, thus the lower moleculer
weight isoforms are present in higher concentrations (6).
The Lp(a) particle is more atherogenic than LDL,
probably because it disturbs the balance between
thrombogenesis and fibrinolysis. High concentrations of
Lp(a) may favor atherosclerotic plaque formation by
inhibiting plasminogen activation (7, 8).

genomic sequences under the blotting
conditions. We determined plasma Lp(a)
levels by ELISA and compared them with the
size of the apo(a) gene. The latter were
determined by dot blotting of plasma samples
from 50 coronary artery disease patients
(angiographically documented) and 50
healthy controls. Our results showed an
inverse relation between the Lp(a) levels and
the apo(a) gene size. This is consistent with
the literature. Our method has no radioactive
steps. It is rapid and easy to perform.

dot blot analysis, DIG-labeling, apo(a) gene.

In the general human population, plasma
concentrations of Lp(a) have been found to vary between
0 and more than 20 mg/dl. When Lp(a) is >30 mg/dl, the
relative risk of coronary atherosclerosis is almost doubled
(9). The concentration of Lp(a) is genetically determined
and only slightly influenced by environmental factors (10,
11). Numerous studies demonstrated an association
between elevated Lp(a) levels and the risk for coronary
heart disease, stroke and vessel reocclusion after aortocoronary bypass surgery (12, 13). Increased
concentrations of apo(B) and Lp(a) may act synergistically
to promote atherosclerosis. Subjects with familial
hypercholesterolemia have a mean Lp(a) concentration
two to three times higher than the mean of the healthy
controls (14).
The apo (a) gene is localized on chromosome 6 (q2627) in a linkage group with the plasminogen gene. Apo
(a) contains three motifs that are also present in
plasminogen: 1. a protease domain with 94% homology
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to the plasminogen’s protease domain, 2. a single
plasminogen like kringle 5-domain, 3. a multiple
plasminogen like kringle-4 domain. The apo(a) and
plasminogen cDNAs have been cloned and the two genes
are closely linked on chromosome 6 (q26-27). The two
cDNA sequences are remarkably similar (15, 16).
The size variation of the apo(a) gene is inversely
related to the plasma Lp(a) concentration because it is
observed that small alleles tend to be dominant over large
alleles in the establishment of the Lp(a) levels (17).
Thus when the gene size increases there is decreased
possibility for the Lp(a) molecule to be assembled from
the large size apo(a) protein which allows low levels of
Lp(a) concentration in the plasma. Conversely, when the
size of the gene is relatively small, then the small alleles
are dominant and the Lp(a) concentration in the plasma
increases. Thus it can be concluded that the Lp(a) level in
the plasma is genetically determined (18). In our study,
we used a probe MP-I, which was hybridized specifically
to the kingle-4 encoding region of the apo(a) gene but
not to the plasminogen or to any other of the apo(a) or
plasminogen pseudogenes. We determined plasma Lp(a)
levels by ELISA and compared them with size of the
apo(a) gene which was detemined by dot blotting in 50
angiographically documented plasma samples from
coronary artery disease patients and 50 healthy controls.
Our results showed inverse correlation between an Lp(a)
levels and the apo (a) gene size.
Materials and Methods

pellet was dried under vacuum and dissolved in sterile
ddH2O. The 3′ End DIG labeling and detection kit was
purchased from Boehringer Mannheim.
Hybridization and detection of the probes
DNA samples were genotyped by dot blotting using a
DIG labeled MP-I probe which was specific to the kringle4 region of the apo(a) gene. 1µg DNA was spotted into
the positively charged nylon membrane. DNA was bound
to the nitrocellulose by applying vacuum for 10 minutes
and fixed by UV cross-linking with transillumination at
254 nm. The membrane was prehybridized at 68°C for 1
hour. The filter was incubated at 54°C for 6 hours to
allow hybridization of the labeled probe. The membrane
was washed and incubated with buffer containing
antidigoxigenin-alkaline phosphatase conjugate. The filter
was incubated with color substrate solution containing 5bromo 4-chloro3-indolyl phosphate (X-phosphate) and
nitroblue tetrazolium salt (NBT). The color precipitate
started to form within a few minutes and the reaction
was usually completed after 16 hours. After the desired
spots or bands were detected, the reaction was stopped
by washing the membrane. The plasma concentration of
total cholesterol, triglycerid and HDL-cholesterol was
determined using a Biotrol kit with a RA-1000
autoanalyser. LDL-cholesterol was calculated by the
Friedewald formula and the plasma concentration of
Lp(a) was determined with a Biotrol Tint ELISA kit.
Statistical methods
Statistical studies were performed with the Student’s
t-test. Significance at p < 0.05 was considered positive.

Subjects
High molecular weight DNA was isolated from
leucocytes of 50 coronary artery disease patients and 50
healthy controls following standard protocols (19). The
purity and amount of DNA samples were determined
spectrophotometrically (20).
Labeling of probe
The MP-I probe was enzymatically labeled at its 3’ end
with terminal transferase by incorporation of a single
digoxigenin-labeled dideoxyuridin triphosphate (DIGddUTP). Tailing buffer (potassium cocadylate, 1mol/l;
Tris-HCL, 0.125mol/l; bovine serum albumine, 1.25
mg/ml; Ph 6.6), CoCl2 solution (25 mmol/l), 100 pmol
MP-1 probe, 50 units terminal transferase, DIG-ddUTP
(1 mmol/l) were mixed and brought to a final volume of
20 µl with ddH20. Incubation was at 37°C for 15
minutes. The labeled oligonucleotide was precipitated
with LiCl2 (4 mol/l). The solution was centrifuged. The

248

Results
To determine the molecular basis for the size
heterogeneity found in the apo(a) protein, the structure
of the apo(a) gene was explored with a genomic blot
using an apo(a) gene specific probe (MP-I:5′TTCATGATCAAGCCACTGGAAATTCCAAAACGATACA-3′),
which does not detect other genomic sequences (Figure
1) Under the blotting conditions we concluded that the
fragments which have a greater number of kringle-4
repeats tended to have more intense color development
than the shorter fragments. Also, after dot blot analysis
we observed dense purple spots on the MP-1 hybridized
DNA samples of the control group, but only faint or no
spots on sample from patients. Since the Lp(a) levels of
the patient group were significantly higher than the levels
of the control group (p<0.001), we concluded that the
level of plasma Lp(a) tends to be inversly related to the
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size of the apo(a) gene. Triglycerides, total cholesterol,
HDL-cholesterol and LDL-cholesterol levels of the patient
and control groups were analyzed and compared within
groups. Triglycerides, total cholesterol and LDLcholesterol levels of the patient group were significantly
higher than the levels of the control group (p < 0.05 )
(Table 1).
After dot-blot analysis we observed dense purple in
the control group, and light, or no spots on the patients’
MP-I hybridized DNA samples (Figure 2).
Discussion
Nucleic acid hybridization is a powerful technique for
the detection of specific, complementary nucleic acid
sequences and is being used extensively for detection of
genetic disorders and molecular pathologies (21). With a

5’

few exceptions, DNA probing techniques require the use
of radioisotopes and toxic DNA extraction techniques
which render the method expensive, potentially
hazardous and time consuming. Most isotopic labeling
techniques use the isotope 32P (half-life 10-14 days) and
require 3-10 days to visualize bands after hybridization
(22). The nonradioactive DNA labeling and detection
system is a safe, stable and sensitive system that is
suitable for a wide variety of nucleic acid hybridization
techniques (23, 24).
In this genomic blotting method we describe the use
of a digoxigenin labeled apo(a) gene specific probe that
has the advantage of using nonradioactive material. An
alternative nonradioactive approach is based on the
biotin-streptavidin system. This system suffers from two
disadvantages; 1) the ubiquitous presence of biotin
(vitamin H) in prokaryotic and eukaryotic cells, 2) a

Figure 1.

Kringle-4
encoding
region of apo (a) gene.
Location of apo(a)
specific probe (MP-1)
within the kringle 4encoding sequence of
the apo(a) gene is
shown. Each kringle-4
encoding repeat is
encoded by two exons,
which are demarcated
by boxes that are filled
in (the first exon) or
open (the sexond
exon). The locations of
Eco RI, Pst I, Bam HI
restrictrion sites are
given. A single kringle4 encoding unit has
been enlarged.

Table 1.

The mean values ±
standard deviations of
patient and control
groups.

3’

Kringle 4 Region

5’

3’
PstI
EcoRI

PstI PstI

BgI II

BamHI
PstI

3’

Total Cholesterol
Triglycerid
HDL-Cholesterol
LDL-Cholesterol
Lp(a)
*

5’

MP-1

PATIENT (n=50) (mg/dl)
mean ± SD

CONTROL (n=50) (mg/dl)
mean ± SD

204.8 ± 47.8*
178.0 ± 75.2*
33.5 ± 11.3
135.8 ± 44.2*
38.3 ± 18.6**

185.0 ± 42.0
108.5 ± 53.9
48.3 ± 13.4
115.3 ± 39.3
25.6 ± 22.7

p < 0.05 , **p < 0.001
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Figure 2.

tendency for streptavidin to bind unspecifically to
immobilizing matrices such as nitrocellulose or nylon. A
nonradioactive
detection
method
based
on
digoxigeninated probes avoids these disadvantages (25).
The factors that influence the apo(a) gene size
detection by dot blotting include the patient’s Lp(a)
concentration, the amount of DNA applied for blotting,
the amount of digoxigenin labeled probe, and the
incubation time for hybridization. The amount of DNA
and incubation times for both prehybridization and
hybridization were kept optimal and the MP-I probe was
added in an optimized way to detect most, if not all, the
kringle-4 domains in the apo(a) gene.
In 30% of the controls with Lp(a) levels, the darkest
bands were observed. This was consistent with the
inverse relation between plasma Lp(a) level and apo(a)
gene size.
Lackner and co-workers used pulsed-field gel
electrophoresis to identify a large Kpn-1 fragment from
the apo (a) gene that contained most of the sequences

MP-I
hybridized
DNA samples.
Dot blotting was
performed using
1µg genomic DNA.
The
blot
was
hybridized
with
100 pmol/ml of the
digoxigenin labeled
apo(a)
kringle-4
specific probe MP-I
as described in
methods.

encoding the kringle-4 repeats (18). This site was
identified by performing PCR using two oligonucleotides;
one from the 3′ end of kringle-5 and the other from the
5′ end of the protease domain of the the apo (a) gene.
Uterman and co-workers suggested an inverse
relationship between the size of apo(a) gene and the
amount of plasma Lp(a) (26). This observation was
confirmed (27). Our findings are also consistent with
these previous studies.
Although this method is not quantitative and not as
sophisticated as pulsed-field gel electrophoresis, PCR and
restriction procedures, our method is simple, rapid and
does not involve any hazardous techniques. As a result it
can be used for common screening of large numbers of
samples.
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